Beeswax
CAS 8012-89-3
Beeswax (CAS 8012-89-3) is a pharmaceutical compound with 0 bioactivity targets and 5 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Beeswax is linked to DTXSID10891981 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BEESWAX | 1356 | SU | MTHSPL |
| beeswax | 1356 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Beeswax used for in pharmaceutical contexts?
Beeswax (CAS 8012-89-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Beeswax?
Beeswax has 5 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Drug eruption, Malignant neoplasm progression, Rash maculo-papular, Skin toxicity, Toxic skin eruption. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Beeswax also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Beeswax with EU status "permitted".
What clinical phase is Beeswax in?
No phase 1-4 clinical development badge is rendered for Beeswax because the matched compound identifier rows do not contain a max-phase value.